AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones
– Cash position expected to fund operations through end of 2023
Related news for (AIM)
- AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
- 24/7 Market News Snapshot 25 September, 2025 – AIM ImmunoTech Inc. (NYSE:AIM)
- AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)
- Today’s Top Performers: MoBot’s Market Review 08/06/25 09:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/06/25 08:00 AM
